Data / Form D filings / Clover Biopharmaceuticals, Ltd.
Clover Biopharmaceuticals, Ltd.: Form D filings
Clover Biopharmaceuticals, Ltd., a biotechnology company in Chengdu, China, filed 6 Form D notices with the SEC between 2021 and 2026. The latest, on April 29, 2026, reports $3.6 million sold of a $3.6 million offering to 9 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- B5-19,BUILDING,HIGH-TECH INCUBATION PARK NO. 1480 NORTH SECTION OF TIANFU AVENUE, Chengdu, China, 61004
- Phone
- 0086-28-8533-6966
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Cayman Islands
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1856491
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | New notice | $3,642,978 | $3,642,978 | 9 | Mar 27, 2026 | sec.gov | |
| Apr 28, 2025 | Amendment | $904,859 | $904,859 | 13 | Apr 2, 2024 | sec.gov | |
| Apr 12, 2024 | New notice | $320,713 | $320,713 | 10 | Apr 2, 2024 | sec.gov | |
| May 9, 2023 | Amendment | Indefinite | $48,882,447 | 74 | Apr 18, 2021 | sec.gov | |
| May 24, 2022 | Amendment | Indefinite | $48,123,054 | 38 | Apr 18, 2021 | sec.gov | |
| Apr 28, 2021 | New notice | Indefinite | $38,071,643 | 27 | Apr 18, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Peng Liang | Executive Officer, Director, Promoter | |
| Joshua Liang | Executive Officer, Director | |
| Xiaodong Wang | Director |
Every Form D from the week of Apr 27, 2026 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Clover Biopharmaceuticals, Ltd. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.